Corium International Inc. (NASDAQ:CORI)’s share price was down 2.3% on Wednesday . The stock traded as low as $4.98 and last traded at $5.41, with a volume of 100,426 shares. The stock had previously closed at $5.29.

Several equities analysts have weighed in on CORI shares. FBR & Co reiterated a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Zacks Investment Research upgraded shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Tuesday, July 19th. Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Corium International in a report on Thursday, June 23rd. Leerink Swann restated a “buy” rating and set a $14.00 price target on shares of Corium International in a report on Wednesday, May 18th. Finally, Jefferies Group restated a “buy” rating and set a $9.00 price target on shares of Corium International in a report on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Corium International has an average rating of “Buy” and a consensus target price of $11.92.

The firm’s market capitalization is $143.32 million. The stock has a 50 day moving average price of $4.45 and a 200 day moving average price of $4.33.

Corium International (NASDAQ:CORI) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. On average, equities analysts anticipate that Corium International Inc. will post ($1.63) EPS for the current fiscal year.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.